ENSYSCE BIOSCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 64.00 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-30
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 12.00K shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 52.00K shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 64.00K shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 555.00K shares, a 384.50% increase from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 114.55K shares.
- ENSYSCE BIOSCIENCES, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 0.00 shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-30 | 12.00K shares derived: sum of 3 quarters · filed 2026-03-30 | 64.00K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 12.00K shares derived: sum of 2 quarters · filed 2025-11-14 | 64.00K shares 10-Q · filed 2025-11-14 | |
| 2025-06-30 | 12.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 64.00K shares 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | 52.00K shares 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 555.00K shares 10-K · filed 2024-03-15 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -2.18M shares derived: sum of 2 quarters · filed 2023-03-30 | -1.87M shares derived: sum of 3 quarters · filed 2023-03-30 | 114.55K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | -2.18M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -1.87M shares derived: sum of 2 quarters · filed 2022-11-14 | 114.55K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 305.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 2.29M shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 1.99M shares 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.00 shares 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |